Zevra Therapeutics
ZVRA
93 hedge funds and large institutions have $78.6M invested in Zevra Therapeutics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 15 reducing their positions, and 11 closing their positions.
228% more call options, than puts
Call options by funds: $985K | Put options by funds: $300K
173% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 15
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
4% more funds holding
Funds holding: 89 → 93 (+4)
4.05% more ownership
Funds ownership: 34.29% → 38.33% (+4%)
3% less capital invested
Capital invested by funds: $80.7M → $78.6M (-$2.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$3.89M |
| 2 |
BlackRock
New York
|
+$1.42M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$1.2M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$861K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$654K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$1.08M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$749K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$527K |
| 4 |
Renaissance Technologies
New York
|
-$202K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$161K |
ZVRA Hedge Fund Activity: Q2 2024 in Review
93 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2024, worth a combined $78.6M — down 2.6% from $80.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ZVRA positions and 11 closed out — a net gain of 4 holders — while 41 added to existing stakes and 15 trimmed.
The largest buyer was Altium Capital Management, adding an estimated $3.89M. The largest seller was Janney Montgomery Scott, cutting an estimated $1.08M.
- 93 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2024, up from 89 in Q1 2024.
- Funds reported $78.6M of Zevra Therapeutics stock for Q2 2024, down 2.6% quarter-over-quarter.
- 15 funds opened new Zevra Therapeutics positions in Q2 2024 and 11 closed out, a net change of +4 holders.
- The largest Zevra Therapeutics buyer in Q2 2024 was Altium Capital Management, an estimated $3.89M added.
- The largest Zevra Therapeutics seller in Q2 2024 was Janney Montgomery Scott, an estimated $1.08M sold.
Based on aggregated 13F filings for Q2 2024.